Abstract
Lung disease is a major morbidity of rheumatoid arthritis (RA). Lung involvement is heterogeneous, and may occur in some form in over 50% of patients with RA. Clinically apparent interstitial lung disease (ILD) affects about 8 % of patients, most commonly usual interstitial pneumonitis. Pulmonary disease is a major cause of death in patients with RA; patients with ILD have a median survival of 2.6 years following diagnosis of the lung disease, lowest in patients with diffuse alveolar damage. Risk factors for RA related lung disease include male sex, older age, smoking, and more severe RA with erosive joint and other extraarticular involvement. Drugs used in management of RA may be associated with pulmonary toxicity, including methotrexate, leflunomide and some biologics. In ILD, lung function studies show a restrictive pattern, with low DLC0 a sensitive parameter of early ILD. High resolution chest computed tomography is sensitive for demonstrating ILD. Treatment of RA associated lung disease is guided by the type of pulmonary disease, recognizing that control of the underlying RA is critical to reducing the impact of disease related comorbidities. Much remains to be done to better understand the pathogenesis and management of this disease manifestation.
Keywords: Interstitial lung disease, lung disease, rheumatoid arthritis.
Current Respiratory Medicine Reviews
Title:The Lung Disease of Rheumatoid Arthritis
Volume: 11 Issue: 2
Author(s): Megan L. Krause, Ana C. Zamora, Robert Vassallo, Jay H. Ryu and Eric L. Matteson
Affiliation:
Keywords: Interstitial lung disease, lung disease, rheumatoid arthritis.
Abstract: Lung disease is a major morbidity of rheumatoid arthritis (RA). Lung involvement is heterogeneous, and may occur in some form in over 50% of patients with RA. Clinically apparent interstitial lung disease (ILD) affects about 8 % of patients, most commonly usual interstitial pneumonitis. Pulmonary disease is a major cause of death in patients with RA; patients with ILD have a median survival of 2.6 years following diagnosis of the lung disease, lowest in patients with diffuse alveolar damage. Risk factors for RA related lung disease include male sex, older age, smoking, and more severe RA with erosive joint and other extraarticular involvement. Drugs used in management of RA may be associated with pulmonary toxicity, including methotrexate, leflunomide and some biologics. In ILD, lung function studies show a restrictive pattern, with low DLC0 a sensitive parameter of early ILD. High resolution chest computed tomography is sensitive for demonstrating ILD. Treatment of RA associated lung disease is guided by the type of pulmonary disease, recognizing that control of the underlying RA is critical to reducing the impact of disease related comorbidities. Much remains to be done to better understand the pathogenesis and management of this disease manifestation.
Export Options
About this article
Cite this article as:
Krause L. Megan, Zamora C. Ana, Vassallo Robert, Ryu H. Jay and Matteson L. Eric, The Lung Disease of Rheumatoid Arthritis, Current Respiratory Medicine Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573398X11666150619184024
DOI https://dx.doi.org/10.2174/1573398X11666150619184024 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Probiotics in Curing Allergic and Inflammatory Conditions - Research Progress and Futuristic Vision
Recent Patents on Inflammation & Allergy Drug Discovery Evaluation of Hyperforin Analogues for Inhibition of 5-lipoxygenase
Medicinal Chemistry Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Editorial [Hot Topic: Towards Tailored Treatment - New Organ-Specific Drug Strategies Interfering in Signal Transduction (Guest Editors: Jai Prakash and Martin H. de Borst)]
Current Signal Transduction Therapy The Role of MIF in Hepatic Function, Oxidative Stress, and Inflammation in Thioacetamide-induced Liver Injury in Mice: Protective Effects of Betaine
Current Medicinal Chemistry Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Predicting Cell Association of Surface-Modified Nanoparticles Using Protein Corona Structure - Activity Relationships (PCSAR)
Current Topics in Medicinal Chemistry Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets
MicroRNA Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design The Physiological/Pathophysiological Significance of Vitamin D in Cancer, Cardiovascular Disorders and Beyond
Current Drug Metabolism New Insights into Acute and Chronic Lung Rejection
Current Respiratory Medicine Reviews Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design Effect of Immunoglobulin Therapy on Blood Viscosity and potential concerns of Thromboembolism, Especially in Patients with Acute Kawasaki Disease
Recent Patents on Cardiovascular Drug Discovery Function and Regulation of Tumor Necrosis Factor Receptor Type 2
Current Medicinal Chemistry